Actinium Pharmaceuticals Inc (ATNM)

$1.58 -0.02 (-1.25%)
Market Cap 49.29M
Revenue (ttm) 0.00
Net Income (ttm) -38.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 334,800
Avg Vol 148,046
Day's Range N/A - N/A
Shares Out 31.20M
Stochastic %K 17%
Beta -0.25
Analysts Strong Sell
Price Target $5.00

Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 677 3870
Address:
100 Park Avenue, 23rd Floor, New York, United States
Biotrad3r
Biotrad3r Oct. 4 at 6:05 PM
$ATNM 200% daily avg volume on Friday, yet ended no change to price during regular trade. Algos are busy at work! But why? 🤔
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 2:04 PM
Inside Cancer Innovation Radiopharmaceuticals RADX What’s Next - YouTube $PSTV $CLRB $ATNM https://www.youtube.com/watch?v=df1JoFcU7gA
0 · Reply
Pinto72
Pinto72 Oct. 3 at 8:05 PM
$ATNM AAVIE!!!!!!🚀🚀🚀🚀🚀🚀 BANKRUPTCY AS SOON!!!🤣🤣🤣🤣🤣
1 · Reply
Snookville
Snookville Oct. 3 at 4:57 PM
$ATNM Seth payday
3 · Reply
gooddoggie
gooddoggie Oct. 3 at 3:57 PM
$ATNM Ok. I finally finished my swing. Ended up with 1180 free shares. It’s somewhat possible those shares are worth something some fine day.
2 · Reply
Pickerbefore
Pickerbefore Oct. 3 at 11:57 AM
$ATNM has management done anything this week to warrant receiving a big paycheck?
1 · Reply
LosStockosDiablo
LosStockosDiablo Oct. 2 at 4:14 PM
$ATNM This need to break out of this tight channel soon either upwards or downwards. Hopefully upwards. Feels like it's been bouncing around between 1.58 -1.65 for a while.
0 · Reply
tvoj
tvoj Oct. 2 at 4:13 PM
$ATNM Just attack is the solution. Again,why ATNM did not sue FDA? https://finance.yahoo.com/news/vanda-pharmaceuticals-announces-collaborative-framework-210200681.html
2 · Reply
mauryrosen
mauryrosen Oct. 2 at 10:08 AM
$ATNM https://www.reuters.com/business/healthcare-pharmaceuticals/takeda-pharmaceutical-exit-cell-therapy-research-2025-10-01/
1 · Reply
Biotrad3r
Biotrad3r Oct. 2 at 6:18 AM
$ATNM Back to pointless selling 11 shares after hours shenanigans i see shorty 🤡🤪
0 · Reply
Latest News on ATNM
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Jul 31, 2025, 8:30 AM EDT - 2 months ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 23, 2025, 11:30 AM EDT - 3 months ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

May 22, 2025, 5:45 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

May 15, 2025, 1:43 PM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 14, 2025, 1:26 PM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

May 6, 2025, 8:45 AM EDT - 5 months ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Apr 30, 2025, 7:25 AM EDT - 5 months ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:30 AM EDT - 5 months ago

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 5 months ago

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Apr 24, 2025, 5:00 AM EDT - 5 months ago

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 19, 2025, 8:20 AM EDT - 6 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Apr 17, 2025, 5:45 AM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

Apr 16, 2025, 10:01 AM EDT - 6 months ago

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

IBTA

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

Mar 28, 2025, 11:57 AM EDT - 6 months ago

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Mar 27, 2025, 8:45 AM EDT - 6 months ago

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Mar 25, 2025, 6:00 AM EDT - 6 months ago

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

Mar 24, 2025, 4:15 PM EDT - 6 months ago

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy

Mar 20, 2025, 8:00 AM EDT - 7 months ago

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

Mar 19, 2025, 8:30 AM EDT - 7 months ago

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

Biotrad3r
Biotrad3r Oct. 4 at 6:05 PM
$ATNM 200% daily avg volume on Friday, yet ended no change to price during regular trade. Algos are busy at work! But why? 🤔
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 2:04 PM
Inside Cancer Innovation Radiopharmaceuticals RADX What’s Next - YouTube $PSTV $CLRB $ATNM https://www.youtube.com/watch?v=df1JoFcU7gA
0 · Reply
Pinto72
Pinto72 Oct. 3 at 8:05 PM
$ATNM AAVIE!!!!!!🚀🚀🚀🚀🚀🚀 BANKRUPTCY AS SOON!!!🤣🤣🤣🤣🤣
1 · Reply
Snookville
Snookville Oct. 3 at 4:57 PM
$ATNM Seth payday
3 · Reply
gooddoggie
gooddoggie Oct. 3 at 3:57 PM
$ATNM Ok. I finally finished my swing. Ended up with 1180 free shares. It’s somewhat possible those shares are worth something some fine day.
2 · Reply
Pickerbefore
Pickerbefore Oct. 3 at 11:57 AM
$ATNM has management done anything this week to warrant receiving a big paycheck?
1 · Reply
LosStockosDiablo
LosStockosDiablo Oct. 2 at 4:14 PM
$ATNM This need to break out of this tight channel soon either upwards or downwards. Hopefully upwards. Feels like it's been bouncing around between 1.58 -1.65 for a while.
0 · Reply
tvoj
tvoj Oct. 2 at 4:13 PM
$ATNM Just attack is the solution. Again,why ATNM did not sue FDA? https://finance.yahoo.com/news/vanda-pharmaceuticals-announces-collaborative-framework-210200681.html
2 · Reply
mauryrosen
mauryrosen Oct. 2 at 10:08 AM
$ATNM https://www.reuters.com/business/healthcare-pharmaceuticals/takeda-pharmaceutical-exit-cell-therapy-research-2025-10-01/
1 · Reply
Biotrad3r
Biotrad3r Oct. 2 at 6:18 AM
$ATNM Back to pointless selling 11 shares after hours shenanigans i see shorty 🤡🤪
0 · Reply
SageSpirits
SageSpirits Oct. 2 at 1:53 AM
$ATNM nearing the end of another amazing gardening season. I gave up on the idea of doing front yard farm gate produce sales and I'm going strictly into plant sales next year. Looking for a side Hustle so I'm studying small scale Nursery opportunities. Looking into niche plants and medicinal herbs. Did excellent this year in the vegetable sales early in the season so I'm going to expand into perennials and have something to sell all season long. Beats waiting for ATNM to pay off. Zone 5, South Central wisconsin.
1 · Reply
SageSpirits
SageSpirits Oct. 2 at 1:41 AM
$ATNM either I have everybody blocked or this stock has gotten so boring that people don't even bother coming here to bash anymore.
1 · Reply
johnny4cures
johnny4cures Oct. 1 at 11:02 PM
$ATNM Sell directly to patients, acc225 or Iomab B through Trumprx
0 · Reply
johnny4cures
johnny4cures Oct. 1 at 9:57 PM
$ATNM Big pharma can buy for the manufacturing once its up and running, save on tariffs, and low cost production Ac-225 for a win win situation!
1 · Reply
mich1282
mich1282 Oct. 1 at 6:37 PM
$ATNM this thing is a joke
0 · Reply
gooddoggie
gooddoggie Oct. 1 at 6:09 PM
$ATNM I don’t know why the market is up today. Consumer spending down for 2nd month in a row. Inflation ticking up, all the usual economic indicators slowly sliding. Those things usually make for a cautious market.
0 · Reply
alcacer123
alcacer123 Oct. 1 at 2:05 PM
$ATNM With the production and marketing of AC225 and its low-cost method, profits of 400 million could be expected with an average demand of 5,000 mCi per year. 5,000 mCi x 90,000 USD/mCi = 450,000 million Cost: 5,000 mCi x 8,000 USD/mCi = 40 million PROFITS = 410 million SPECTACULAR, let's go, Seth, progress.
2 · Reply
highnihilism
highnihilism Oct. 1 at 1:11 PM
$ATNM Actinium Pharmaceuticals Trades: 8 | Total $: 191 | 0.32 × 90-Day Avg $: 603 | Call $: 191 | Put $: 0 | Single-Leg: 88% | Multi-Leg: 12% | Contingent: – $TTEC Ttec Holdings Trades: 6 | Total $: 3.8 K | 0.26 × 90-Day Avg $: 14.6 K | Call $: 190 | Put $: 3.6 K | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $SCHP Schwab U.S. Tips ETF Trades: 4 | Total $: 190 | 0.24 × 90-Day Avg $: 782 | Call $: 190 | Put $: 0 | Single-Leg: 75% | Multi-Leg: 25% | Contingent: – $ARKO Arko Corp. Trades: 2 | Total $: 190 | 0.07 × 90-Day Avg $: 2.9 K | Call $: 190 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
luzongeezer
luzongeezer Oct. 1 at 7:24 AM
$ATNM My daughter's school, and what I force into my head when ATNM comes to mind: "Jolly Hearts! Jolly Hearts!"
2 · Reply
gooddoggie
gooddoggie Oct. 1 at 4:21 AM
$ATNM The gov shutdown won’t be a problem for ATNM unless the FDA remains shutdown until 2028 Q4.
1 · Reply
Pinto72
Pinto72 Sep. 30 at 7:37 PM
$IOBT Bag holders on this board sound exactly the same as the Bag holders on the $ATNM board. 🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!🤣🤣🤣🤣🤣
0 · Reply
Nibbler
Nibbler Sep. 30 at 5:06 PM
$ATNM Its been so long that i looked at this stock after losing $$ here. Good time to come back? Any near term catalysts?
2 · Reply